Sugi Predict

Sugi Predict / Compounds / SCHEMBL479037

SCHEMBL479037

SCHEMBL479037

CC(C)(C)OC(=O)NC(Cc1cccnc1)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 1/20 0.61
▸ CYP3A4 P08684 9/20 0.56
▸ SCN9A Q15858 1/20 0.54
▸ CTSS P25774 2/20 0.54
▸ CTSL P07711 1/20 0.54
▸ CTSB P07858 1/20 0.54
▸ CTSK P43235 1/20 0.54
▸ PPARA Q07869 2/20 0.53
▸ PPARG P37231 1/20 0.53
▸ GPR132 Q9UNW8 1/20 0.52
▸ ITGB3 P05106 1/20 0.52
▸ ITGA2B P08514 1/20 0.52
▸ ITGA4 P13612 1/20 0.50
▸ ITGB7 P26010 1/20 0.50
▸ PTPN1 P18031 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30547269 1.00 ACE (0.61) ACECYP3A4SCN9ACTSSCTSL
SCHEMBL30655780 1.00 ACE (0.61) ACECYP3A4SCN9ACTSSCTSL
SCHEMBL29401567 1.00 ACE (0.61) ACECYP3A4SCN9ACTSSCTSL
SCHEMBL479035 1.00 ACE (0.61) ACECYP3A4SCN9ACTSSCTSL
SCHEMBL606221 1.00 ACE (0.61) ACECYP3A4SCN9ACTSSCTSL
SCHEMBL3820572 0.91 ACE (0.53) ACECYP3A4SCN9ACTSSCTSL
SCHEMBL2367464 0.90 ACE (0.52) ACECYP3A4SCN9ACTSSCTSL
SCHEMBL13323784 0.90 ACE (0.52) ACECYP3A4SCN9ACTSSCTSL
SCHEMBL8125933 0.90 CYP3A4 (0.52) ACECYP3A4SCN9ACTSSCTSL
SCHEMBL29588090 0.90 CYP3A4 (0.52) ACECYP3A4SCN9ACTSSCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4534524-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PeptiDream Inc. (JP) 2025-04-09 — — EP disclosed
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-02-20 — — US disclosed
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof RAZE THERAPEUTICS, INC. (US) 2025-01-07 — — US disclosed
US-20240262792-A1 USP30 INHIBITORS AND USES THEREOF VINCERE BIOSCIENCES, INC. 2024-08-08 — — US disclosed
WO-2024151615-A1 MRNA DISPLAY LIBRARIES AND METHODS OF USE THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2024-07-18 — — WO disclosed
US-12029739-B2 SHP2 inhibitor and use thereof KANAPH THERAPEUTICS INC. (KR) 2024-07-09 — — US disclosed
US-20240189306-A1 SHP2 INHIBITOR AND USE THEREOF KANAPH THERAPEUTICS INC. (KR) 2024-06-13 — — US disclosed
EP-4368625-A1 SHP2 INHIBITOR AND USE THEREOF Kanaph Therapeutics Inc. (KR) 2024-05-15 — — EP disclosed
CN-117916242-A SHP2 inhibitors and uses thereof 治纳辅医药科技有限公司 2024-04-19 — — CN disclosed
US-11952365-B2 Anti-viral compounds ALIGOS THERAPEUTICS, INC. (US) 2024-04-09 — — US disclosed
WO-1996018644-A1 AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1996-06-20 — — WO disclosed
WO-1995035313-A1 3-AMINO-2-OXO-1-PIPERIDINEACETIC DERIVATIVES CONTAINING AN ARGININE MIMIC AS ENZYME INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1995-12-28 — — WO disclosed
WO-1995035312-A1 ARGININE MIMIC DERIVATIVES AS ENZYME INHIBITORS CORVAS INTERNATIONAL, INC. (US) 1995-12-28 — — WO disclosed
EP-0680488-A1 2,6-DIAMINOPURINE DERIVATIVES GLAXO GROUP LIMITED (GB) 1995-11-08 — — EP disclosed
US-5393875-A Hypotensive, cardiotonic and antiischemic agents HOFFMANN-LA ROCHE INC. (US) 1995-02-28 — — US disclosed
WO-1994017090-A1 2,6-DIAMINOPURINE DERIVATIVES GLAXO GROUP LIMITED (GB) 1994-08-04 — — WO disclosed
EP-0509354-A2 Amino acid derivatives F. HOFFMANN-LA ROCHE AG (CH) 1992-10-21 — — EP disclosed
US-5091396-A Guanidinoalkanoylaspartylpyridine derivatives; anticoagulants MONSANTO CO. (US) 1992-02-25 — — US disclosed
EP-0454651-A2 Novel platelet-aggregation inhibitors MONSANTO COMPANY (US) 1991-10-30 — — EP disclosed
US-5037808-A Indolyl platelet-aggregation inhibitors MONSANTO CO. (US) 1991-08-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187728-B2 Caffeine inhibitors of MTHFD2 and uses thereof MTHFD2, MTHFD1, NUDT15 ACE 2233/4885CYP3A4 830/4885SCN9A 4461/4885
US-11952365-B2 Anti-viral compounds EIF2AK2, ZC3HAV1, HAVCR2 ACE 7/4885CYP3A4 2328/4885SCN9A 1034/4885
US-20240189306-A1 SHP2 INHIBITOR AND USE THEREOF PTPN1, PTPN5, PTPN2 ACE 1077/4885CYP3A4 4740/4885SCN9A 2748/4885
US-12029739-B2 SHP2 inhibitor and use thereof PTPN1, PTPN5, PTPN2 ACE 1077/4885CYP3A4 4740/4885SCN9A 2748/4885
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 ACE 3963/4885CYP3A4 3093/4885SCN9A 2327/4885
US-20240262792-A1 USP30 INHIBITORS AND USES THEREOF USP30, USP28, USP1 ACE 2383/4885CYP3A4 3893/4885SCN9A 4325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.